A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Maj Schneider Thomsen; Torben Moos

doi:10.1016/j.medj.2022.11.006

A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Maj Schneider Thomsen, Torben Moos^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Abstract

The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

Originalsprog	Engelsk
Tidsskrift	Med (New York, N.Y.)
Vol/bind	3
Udgave nummer	12
Sider (fra-til)	815-817
Antal sider	3
ISSN	2666-6340
DOI	https://doi.org/10.1016/j.medj.2022.11.006
Status	Udgivet - 9 dec. 2022

Bibliografisk note

Adgang til dokumentet

10.1016/j.medj.2022.11.006

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

@article{7347a0d693a9403f992ed32bec73c93f,

title = "A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain",

abstract = "The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.",

keywords = "Antibodies, Bispecific/therapeutic use, Biological Transport, Blood-Brain Barrier/metabolism, Brain/metabolism",

author = "Thomsen, {Maj Schneider} and Torben Moos",

year = "2022",

month = dec,

day = "9",

doi = "10.1016/j.medj.2022.11.006",

language = "English",

volume = "3",

pages = "815--817",

journal = "Med (New York, N.Y.)",

issn = "2666-6340",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

AU - Thomsen, Maj Schneider

AU - Moos, Torben

PY - 2022/12/9

Y1 - 2022/12/9

N2 - The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

AB - The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.1 report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

KW - Antibodies, Bispecific/therapeutic use

KW - Biological Transport

KW - Blood-Brain Barrier/metabolism

KW - Brain/metabolism

U2 - 10.1016/j.medj.2022.11.006

DO - 10.1016/j.medj.2022.11.006

M3 - Comment/debate

C2 - 36495860

SN - 2666-6340

VL - 3

SP - 815

EP - 817

JO - Med (New York, N.Y.)

JF - Med (New York, N.Y.)

IS - 12

ER -

A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Abstract

Bibliografisk note

Adgang til dokumentet

AUB Link

Fingeraftryk

Citationsformater